Core Viewpoint - Watson Bio emphasizes the importance of biomanufacturing as a national strategic emerging industry, highlighting its economic, social, and environmental benefits for sustainable development [1] Group 1: Company Mission and Strategy - The company adheres to the mission of "sowing health and creating beauty," aiming for "everyone to be born healthy" [1] - It actively responds to technological innovations and changes in the industry environment by integrating production, education, research, and application [1] - The company is focused on enhancing its technological innovation capabilities while leveraging existing industrial advantages [1] Group 2: Product Development and Pipeline - In addition to its existing human vaccine business, the company is expanding its product pipeline in biomanufacturing, which includes nutrients, natural active ingredients, and functional proteins [1] - The company is systematically advancing research and industrialization of these new product categories [1] - Further product details will be disclosed in future company communications [1]

Core Insights - Watson Bio achieved a revenue of 560 million yuan in Q3 2025, with a net profit attributable to shareholders increasing by 40.19% year-on-year [1] - The company is expanding its overseas market, with product export amounts growing by 6.32% compared to the same period last year [1] - Watson Bio is strategically positioning itself in two new business areas: micro-ecological health and synthetic biology manufacturing, laying a solid foundation for long-term growth [1] Group 1: Micro-Ecological Health - In response to the national "preventive healthcare" strategy, Watson Bio is expanding its product pipeline and developing "core microbiome therapy" for precise micro-ecological health and functional nutrition interventions [2] - The company signed exclusive licensing agreements with Notitia Biotechnologies Company to develop and commercialize core microbiome analysis and targeted transplantation technologies in mainland China, Hong Kong, and Macau [2] - This dual-track approach aims to provide comprehensive health solutions covering both hospital treatment and outpatient management, aligning with national policies on non-drug interventions and chronic disease prevention [2] Group 2: Synthetic Biology Manufacturing - Watson Bio is seizing opportunities in the synthetic biology manufacturing sector, leveraging local biodiversity, green energy, and biomass resources [3] - The company established Aisenze Biotechnology (Kunming) Co., Ltd. to focus on the industrialization of precision photobiological synthesis of natural products for health [3] - Ongoing industrialization and market preparation efforts are expected to contribute new momentum for the company's long-term development [3]